Dizal files for HKEX listing with Goldman Sachs and Huatai International as joint sponsors; sunvozertinib licensed globally to AstraZeneca for USD 600 million upfront

NewTimeSpace News: On 27 August 2026, Dizal Pharmaceutical Co., Ltd. filed a listing application with HKEX, with Goldman Sachs and Huatai International acting as joint sponsors. The Company is a commercial-stage biopharmaceutical company whose core therapeutic areas are oncology and hematological diseases. During the track record period, it developed and commercialized in Mainland China golidocitinib (Gao Ruizhe), a next-generation highly selective Janus kinase 1 (JAK1) inhibitor, and sunvozertinib (Shuwozhe).

Sunvozertinib is the world's first small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of lung cancer with EGFR exon 20 insertion (exon20ins) mutations, and has been launched in Mainland China and approved in the United States, being the first lung cancer drug developed in China to receive Breakthrough Therapy designations from both the US FDA and China's NMPA. As of the last practicable date, sunvozertinib is the only small-molecule drug recommended by the authoritative NCCN guidelines for the treatment of EGFR exon20ins NSCLC, and the only targeted drug included in China's National Reimbursement Drug List (NRDL) for the relapsed or refractory (r/r) EGFR exon20ins indication. Golidocitinib is the world's first and only JAK1 inhibitor approved for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL), having received Fast Track and Orphan Drug designations from the US FDA, and has also been included in the NRDL.

According to the announcement, prior to the establishment of Dizal in 2017, the Company was AstraZeneca's global oncology translational science center — the Asian Innovation Medicines and Early Development (iMED Asia). The Company's pipeline comprises the out-licensed sunvozertinib, the marketed golidocitinib, one candidate drug (DZD8586) at the registration-stage clinical phase, three assets at the post-concept-validation stage and one asset at the early clinical stage.

On 14 July 2026, the Company entered into a license agreement with AstraZeneca UK Limited, granting AstraZeneca an exclusive license to develop and commercialize sunvozertinib globally. AstraZeneca is expected to pay a one-time, non-refundable and non-creditable upfront payment of USD 600.0 million as partial consideration, which, according to CIC, represents the largest upfront payment in a single-asset license-out transaction for a Chinese small-molecule drug to date. The Company is also entitled to development milestone payments of up to USD 400.0 million in aggregate and sales milestone payments of up to USD 500.0 million in aggregate, subject to the achievement of specified development, regulatory and sales milestones, as well as tiered royalties of up to a low double-digit percentage on global sales of sunvozertinib.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.